PR-000608

PR-608
Clinical data
Other names	PR 000608
Identifiers
	IUPAC name 1-(4,4-Bis(4-fluorophenyl)butyl)-4-(2-hydroxy-3-phenylaminopropyl)piperazine;
CAS Number	143759-63-1;
PubChem CID	3072701;
ChemSpider	2332014;
ChEMBL	ChEMBL58192;
Chemical and physical data
Formula	C29H35F2N3
Molar mass	463.617 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CN(CCN1CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)CC(CNC4=CC=CC=C4)O;
	InChI InChI=1S/C29H35F2N3O/c30-25-12-8-23(9-13-25)29(24-10-14-26(31)15-11-24)7-4-16-33-17-19-34(20-18-33)22-28(35)21-32-27-5-2-1-3-6-27/h1-3,5-6,8-15,28-29,32,35H,4,7,16-22H2; Key:YIBOKAQCZWKXIM-UHFFFAOYSA-N;

PR-608 is a potent dopamine reuptake inhibitor belonging to the diphenylbutylpiperazine class of agents (related to the diphenylbutylpiperidine class). Other members of this class include amperozide, lidoflazine, difluanazine, FG5865 and FG-5893.

Some sources claim PR-608 is related to vanoxerine. However, it is important to make the distinction that the GBR class of agents are known to be derived from diphenhydramine (or more specifically flunamine) as exemplified by S-350. The agents of this class all bear a benzhydryl-ethyl-ether functional group.

PR-608 was invented and developed in Japan and was patented in the 1990's to Pola Orbis Holdings Inc.